MLEC Quote, Financials, Valuation and Earnings

Auna SA has a net margin of -166.47% compared to Moolec Science SA's net margin of 4.74%. Moolec Science SA's return on equity of -93.42% beat Auna SA's return on equity of 11.53%.

Moolec Science SA has a consensus price target of --, signalling upside risk potential of 11743.66%. On the other hand Auna SA has an analysts' consensus of $10.42 which suggests that it could grow by 124.01%. Given that Moolec Science SA has higher upside potential than Auna SA, analysts believe Moolec Science SA is more attractive than Auna SA.

Moolec Science SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Auna SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Moolec Science SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Auna SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moolec Science SA pays -- of its earnings as a dividend. Auna SA pays out -- of its earnings as a dividend.

Moolec Science SA quarterly revenues are $1.5M, which are smaller than Auna SA quarterly revenues of $316.1M. Moolec Science SA's net income of -$2.5M is lower than Auna SA's net income of $15M. Notably, Moolec Science SA's price-to-earnings ratio is -- while Auna SA's PE ratio is 6.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moolec Science SA is 0.96x versus 0.30x for Auna SA. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -166.47% compared to Moolec Science SA's net margin of --. Moolec Science SA's return on equity of -93.42% beat CEL-SCI Corp.'s return on equity of -230.36%.

Moolec Science SA has a consensus price target of --, signalling upside risk potential of 11743.66%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 718.88%. Given that Moolec Science SA has higher upside potential than CEL-SCI Corp., analysts believe Moolec Science SA is more attractive than CEL-SCI Corp..

Moolec Science SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Moolec Science SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moolec Science SA pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Moolec Science SA quarterly revenues are $1.5M, which are larger than CEL-SCI Corp. quarterly revenues of --. Moolec Science SA's net income of -$2.5M is higher than CEL-SCI Corp.'s net income of -$6.1M. Notably, Moolec Science SA's price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moolec Science SA is 0.96x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Eurofins Scientific SE has a net margin of -166.47% compared to Moolec Science SA's net margin of --. Moolec Science SA's return on equity of -93.42% beat Eurofins Scientific SE's return on equity of 8.55%.

Moolec Science SA has a consensus price target of --, signalling upside risk potential of 11743.66%. On the other hand Eurofins Scientific SE has an analysts' consensus of -- which suggests that it could fall by --. Given that Moolec Science SA has higher upside potential than Eurofins Scientific SE, analysts believe Moolec Science SA is more attractive than Eurofins Scientific SE.

Moolec Science SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eurofins Scientific SE has a beta of 0.637, suggesting its less volatile than the S&P 500 by 36.263%.

Moolec Science SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eurofins Scientific SE offers a yield of 1.71% to investors and pays a quarterly dividend of $0.68 per share. Moolec Science SA pays -- of its earnings as a dividend. Eurofins Scientific SE pays out 28.14% of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moolec Science SA quarterly revenues are $1.5M, which are larger than Eurofins Scientific SE quarterly revenues of --. Moolec Science SA's net income of -$2.5M is higher than Eurofins Scientific SE's net income of --. Notably, Moolec Science SA's price-to-earnings ratio is -- while Eurofins Scientific SE's PE ratio is 28.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moolec Science SA is 0.96x versus 1.75x for Eurofins Scientific SE. Usually stocks with elevated PS ratios are considered overvalued.

Sofgen Pharma SA has a net margin of -166.47% compared to Moolec Science SA's net margin of --. Moolec Science SA's return on equity of -93.42% beat Sofgen Pharma SA's return on equity of --.

Moolec Science SA has a consensus price target of --, signalling upside risk potential of 11743.66%. On the other hand Sofgen Pharma SA has an analysts' consensus of -- which suggests that it could grow by 9900%. Given that Moolec Science SA has higher upside potential than Sofgen Pharma SA, analysts believe Moolec Science SA is more attractive than Sofgen Pharma SA.

Moolec Science SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sofgen Pharma SA has a beta of 61.716, suggesting its more volatile than the S&P 500 by 6071.584%.

Moolec Science SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sofgen Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moolec Science SA pays -- of its earnings as a dividend. Sofgen Pharma SA pays out -- of its earnings as a dividend.

Moolec Science SA quarterly revenues are $1.5M, which are larger than Sofgen Pharma SA quarterly revenues of --. Moolec Science SA's net income of -$2.5M is higher than Sofgen Pharma SA's net income of --. Notably, Moolec Science SA's price-to-earnings ratio is -- while Sofgen Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moolec Science SA is 0.96x versus 0.01x for Sofgen Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.